BridgeBio Pharma, Inc. Basic Shares Outstanding (Weighted Average)
BridgeBio Pharma, Inc. (BBIO) reported Basic Shares Outstanding (Weighted Average) of 195.79 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-10
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 195.79M shares, a 2.77% increase year-over-year.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 194.79M shares, a 2.44% increase year-over-year.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 193.57M shares, a 2.17% increase year-over-year.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 191.85M shares, a 1.77% increase year-over-year.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 191.53M shares, a 2.93% increase from fiscal 2024.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 186.08M shares, a 14.30% increase from fiscal 2023.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 162.79M shares, a 10.39% increase from fiscal 2022.
- BridgeBio Pharma, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 147.47M shares, a 2.16% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 195.79M shares 10-Q · filed 2026-08-10 | 195.29M shares 10-Q · filed 2026-08-10 | 194.72M shares derived: average of 3 quarters · filed 2026-08-10 | 194.00M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 194.79M shares 10-Q · filed 2026-05-07 | 194.18M shares derived: average of 2 quarters · filed 2026-05-07 | 193.41M shares derived: average of 3 quarters · filed 2026-05-07 | 192.68M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | 193.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 192.71M shares derived: average of 2 quarters · filed 2026-02-24 | 191.98M shares derived: average of 3 quarters · filed 2026-08-10 | 191.53M shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 191.85M shares 10-Q · filed 2025-10-29 | 191.19M shares derived: average of 2 quarters · filed 2026-08-10 | 190.85M shares 10-Q · filed 2025-10-29 | 190.49M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | 190.52M shares 10-Q · filed 2026-08-10 | 190.33M shares 10-Q · filed 2026-08-10 | 190.04M shares derived: average of 3 quarters · filed 2026-08-10 | 189.66M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | 190.15M shares 10-Q · filed 2026-05-07 | 189.80M shares derived: average of 2 quarters · filed 2026-05-07 | 189.37M shares derived: average of 3 quarters · filed 2026-05-07 | 188.93M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 189.46M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 188.99M shares derived: average of 2 quarters · filed 2026-02-24 | 188.52M shares derived: average of 3 quarters · filed 2026-02-24 | 186.08M shares 10-K · filed 2026-02-24 |
| 2024-09-30 | 188.51M shares 10-Q · filed 2025-10-29 | 188.05M shares derived: average of 2 quarters · filed 2025-10-29 | 184.95M shares 10-Q · filed 2025-10-29 | 182.32M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | 187.59M shares 10-Q · filed 2025-08-05 | 183.15M shares 10-Q · filed 2025-08-05 | 180.26M shares derived: average of 3 quarters · filed 2026-02-24 | 176.02M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | 178.71M shares 10-Q · filed 2025-04-29 | 176.60M shares derived: average of 2 quarters · filed 2026-02-24 | 172.17M shares derived: average of 3 quarters · filed 2026-02-24 | 169.26M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | 174.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 168.90M shares derived: average of 2 quarters · filed 2026-02-24 | 166.11M shares derived: average of 3 quarters · filed 2026-02-24 | 162.79M shares 10-K · filed 2026-02-24 |
| 2023-09-30 | 163.31M shares 10-Q · filed 2024-11-12 | 161.92M shares derived: average of 2 quarters · filed 2024-11-12 | 158.89M shares 10-Q · filed 2024-11-12 | 156.46M shares derived: average of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | 160.54M shares 10-Q · filed 2024-08-01 | 156.65M shares 10-Q · filed 2024-08-01 | 154.18M shares derived: average of 3 quarters · filed 2025-02-20 | 152.62M shares derived: average of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | 152.65M shares 10-Q · filed 2024-05-02 | 151.01M shares derived: average of 2 quarters · filed 2025-02-20 | 149.98M shares derived: average of 3 quarters · filed 2025-02-20 | 149.16M shares derived: average of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | 149.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | 148.65M shares derived: average of 2 quarters · filed 2025-02-20 | 148.00M shares derived: average of 3 quarters · filed 2025-02-20 | 147.47M shares 10-K · filed 2025-02-20 |
| 2022-09-30 | 147.94M shares 10-Q · filed 2023-11-02 | 147.31M shares derived: average of 2 quarters · filed 2023-11-02 | 146.84M shares 10-Q · filed 2023-11-02 | 146.45M shares derived: average of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | 146.68M shares 10-Q · filed 2023-08-03 | 146.29M shares 10-Q · filed 2023-08-03 | 145.95M shares derived: average of 3 quarters · filed 2024-02-22 | 146.13M shares derived: average of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | 145.88M shares 10-Q · filed 2023-05-04 | 145.59M shares derived: average of 2 quarters · filed 2024-02-22 | 145.95M shares derived: average of 3 quarters · filed 2024-02-22 | 146.15M shares derived: average of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | 145.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 145.98M shares derived: average of 2 quarters · filed 2024-02-22 | 146.24M shares derived: average of 3 quarters · filed 2024-02-22 | 144.36M shares 10-K · filed 2024-02-22 |
| 2021-09-30 | 146.66M shares 10-Q · filed 2022-11-03 | 146.71M shares derived: average of 2 quarters · filed 2022-11-03 | 144.04M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 146.75M shares 10-Q · filed 2022-08-04 | 142.71M shares 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | 118.00M shares 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |